1. Home
  2. SERA vs GOSS Comparison

SERA vs GOSS Comparison

Compare SERA & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sera Prognostics Inc.

SERA

Sera Prognostics Inc.

N/A

Current Price

$2.09

Market Cap

75.2M

Sector

Health Care

ML Signal

N/A

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$12.10

Market Cap

83.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SERA
GOSS
Founded
2008
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.2M
83.2M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
SERA
GOSS
Price
$2.09
$12.10
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$4.19
AVG Volume (30 Days)
21.3K
12.9M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
32.32
N/A
EPS
N/A
N/A
Revenue
$81,000.00
$48,471,000.00
Revenue This Year
$554.81
N/A
Revenue Next Year
$517.27
$201.64
P/E Ratio
N/A
N/A
Revenue Growth
5.19
N/A
52 Week Low
$1.56
$0.11
52 Week High
$3.95
$12.52

Technical Indicators

Market Signals
Indicator
SERA
GOSS
Relative Strength Index (RSI) 54.67 96.52
Support Level $1.88 $0.18
Resistance Level $2.12 $12.52
Average True Range (ATR) 0.07 0.51
MACD 0.00 1.27
Stochastic Oscillator 59.03 98.02

Price Performance

Historical Comparison
SERA
GOSS

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).

Share on Social Networks: